Mei Ying W Yu

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma
    Mei Ying W Yu
    Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:7705-10. 2004
  2. ncbi Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees
    Pei Zhang
    Division of Hematology and Laboratory of Biophysics, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:9214-9. 2006
  3. ncbi Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture
    Erica Silberstein
    Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Pathog 6:e1000910. 2010
  4. ncbi Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples
    Mei Ying W Yu
    Division of Hematology, Center for Biologics Evaluation and Research, FDA, Warren Grant Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
    Transfusion 50:1712-21. 2010
  5. ncbi Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing
    Yansheng Geng
    Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Transfusion 47:883-9. 2007
  6. ncbi Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma
    Pei Zhang
    Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 104:8449-54. 2007
  7. ncbi Quantification of hepatitis B virus genomes and infectivity in human serum samples
    Chu Chieh Hsia
    Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Bethesda, Maryland, USA
    Transfusion 46:1829-35. 2006
  8. ncbi Measles-virus-neutralizing antibodies in intravenous immunoglobulins
    Susette Audet
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    J Infect Dis 194:781-9. 2006
  9. ncbi International collaborative study to assess candidate reference preparations to control the level of anti-D in IVIG for use in Europe and the United States
    Susan J Thorpe
    National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    Biologicals 34:209-12. 2006
  10. ncbi HCV core antigen as an alternative to NAT to detect HCV viremia
    Christina A Raker
    Transfusion 44:307-8. 2004

Collaborators

Detail Information

Publications10

  1. ncbi Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma
    Mei Ying W Yu
    Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:7705-10. 2004
    ..Immune globulins made from anti-HCV-positive plasma and containing broadly reactive neutralizing antibodies may provide a method of preventing HCV infection...
  2. ncbi Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees
    Pei Zhang
    Division of Hematology and Laboratory of Biophysics, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:9214-9. 2006
    ....
  3. ncbi Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture
    Erica Silberstein
    Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Pathog 6:e1000910. 2010
    ..This virus constitutes a novel tool for the study of one of the most relevant strains of HCV, genotype 1b, which will now be available for HCV life cycle research and useful for the development of new therapeutics...
  4. ncbi Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples
    Mei Ying W Yu
    Division of Hematology, Center for Biologics Evaluation and Research, FDA, Warren Grant Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
    Transfusion 50:1712-21. 2010
    ..However, reports of transmission by single-donor blood components are rare. In this prospective study, paired donor-recipient samples were used to investigate the transfusion risk...
  5. ncbi Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing
    Yansheng Geng
    Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Transfusion 47:883-9. 2007
    ..In this study, the extent of B19 DNA contamination in commercial Factor VIII concentrates, that is, antihemophilic factor (human) (AHF), manufactured before and after B19 NAT screening was implemented, was determined...
  6. ncbi Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma
    Pei Zhang
    Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 104:8449-54. 2007
    ....
  7. ncbi Quantification of hepatitis B virus genomes and infectivity in human serum samples
    Chu Chieh Hsia
    Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Bethesda, Maryland, USA
    Transfusion 46:1829-35. 2006
    ....
  8. ncbi Measles-virus-neutralizing antibodies in intravenous immunoglobulins
    Susette Audet
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    J Infect Dis 194:781-9. 2006
    ..A reduction in mnAbs also correlated with the loss of either IgG1 and IgG3, possibly because of certain manufacturing procedures, or bivalent antibodies (i.e., intact IgG and F(ab')2), because of fragmentation...
  9. ncbi International collaborative study to assess candidate reference preparations to control the level of anti-D in IVIG for use in Europe and the United States
    Susan J Thorpe
    National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    Biologicals 34:209-12. 2006
    ....
  10. ncbi HCV core antigen as an alternative to NAT to detect HCV viremia
    Christina A Raker
    Transfusion 44:307-8. 2004